ARTV vs. OCGN, ACTU, MDWD, NVCT, ANNX, IPHA, CRGX, VYGR, YMAB, and IVA
Should you be buying Artiva Biotherapeutics stock or one of its competitors? The main competitors of Artiva Biotherapeutics include Ocugen (OCGN), Actuate Therapeutics (ACTU), MediWound (MDWD), Nuvectis Pharma (NVCT), Annexon (ANNX), Innate Pharma (IPHA), CARGO Therapeutics (CRGX), Voyager Therapeutics (VYGR), Y-mAbs Therapeutics (YMAB), and Inventiva (IVA). These companies are all part of the "pharmaceutical products" industry.
Artiva Biotherapeutics vs.
Artiva Biotherapeutics (NASDAQ:ARTV) and Ocugen (NASDAQ:OCGN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, community ranking, risk, dividends, earnings and valuation.
Artiva Biotherapeutics has a net margin of 0.00% compared to Ocugen's net margin of -532.51%. Artiva Biotherapeutics' return on equity of 0.00% beat Ocugen's return on equity.
Artiva Biotherapeutics currently has a consensus target price of $19.40, indicating a potential upside of 879.80%. Ocugen has a consensus target price of $6.00, indicating a potential upside of 556.53%. Given Artiva Biotherapeutics' higher probable upside, research analysts clearly believe Artiva Biotherapeutics is more favorable than Ocugen.
10.3% of Ocugen shares are owned by institutional investors. 21.4% of Artiva Biotherapeutics shares are owned by insiders. Comparatively, 4.4% of Ocugen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Artiva Biotherapeutics has higher earnings, but lower revenue than Ocugen.
In the previous week, Artiva Biotherapeutics had 3 more articles in the media than Ocugen. MarketBeat recorded 4 mentions for Artiva Biotherapeutics and 1 mentions for Ocugen. Ocugen's average media sentiment score of 1.26 beat Artiva Biotherapeutics' score of -0.21 indicating that Ocugen is being referred to more favorably in the news media.
Ocugen received 100 more outperform votes than Artiva Biotherapeutics when rated by MarketBeat users. However, 100.00% of users gave Artiva Biotherapeutics an outperform vote while only 71.43% of users gave Ocugen an outperform vote.
Summary
Artiva Biotherapeutics beats Ocugen on 9 of the 13 factors compared between the two stocks.
Get Artiva Biotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARTV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Artiva Biotherapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ARTV) was last updated on 5/23/2025 by MarketBeat.com Staff
Buy ARTV Stock Free ARTV Stock Alerts